Similar articles

• Did Prasugrel and Ticagrelor Offer the Same Benefit in Patients with Acute Coronary Syndromes after Percutaneous Coronary Interventions Compared to Clopidogrel? Insights from Randomized Clinical Trials, Registries and Meta-analysis.

  Rodriguez AE, Rodriguez-Granillo AM, Ascarrunz SD, Peralta-Bazan F, Cho MY. Rodriguez AE, et al. Curr Pharm Des. 2018;24(4):465-477. doi: 10.2174/1381612824666180108121834. Curr Pharm Des. 2018. PMID: 29308737 Review.
• Comparison of prasugrel and ticagrelor in patients with acute coronary syndrome undergoing percutaneous coronary intervention: A meta-analysis of randomized and non-randomized studies.

  Watti H, Dahal K, Zabher HG, Katikaneni P, Modi K, Abdulbaki A. Watti H, et al. Int J Cardiol. 2017 Dec 15;249:66-72. doi: 10.1016/j.ijcard.2017.07.103. Int J Cardiol. 2017. PMID: 29121759
• Head to head comparison of Prasugrel versus Ticagrelor in patients with acute coronary syndrome: a systematic review and meta-analysis of randomized trials.

  Bundhun PK, Shi JX, Huang F. Bundhun PK, et al. BMC Pharmacol Toxicol. 2017 Dec 12;18(1):80. doi: 10.1186/s40360-017-0189-7. BMC Pharmacol Toxicol. 2017. PMID: 29233189 Free PMC article. Review.
• [The ISAR-REACT 5 trial: is there a winner between prasugrel and ticagrelor in acute coronary syndromes?].

  Ferlini M, Galvani M, Visconti LO. Ferlini M, et al. G Ital Cardiol (Rome). 2020 Mar;21(3):171-174. doi: 10.1714/3306.32764. G Ital Cardiol (Rome). 2020. PMID: 32100728 Italian. No abstract available.
• Switching to Clopidogrel in Patients With Acute Coronary Syndrome Managed With Percutaneous Coronary Intervention Initially Treated With Prasugrel or Ticagrelor: Systematic Review and Meta-analysis.

  Hong J, Turgeon RD, Pearson GJ. Hong J, et al. Ann Pharmacother. 2019 Oct;53(10):997-1004. doi: 10.1177/1060028019845334. Epub 2019 Apr 18. Ann Pharmacother. 2019. PMID: 30999764